Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Cancer Treatment Reports
|
October 1, 1984
Phase II trial of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial
G Y Locker, V Lanzotti, D Sweet, et al.
Cancer Research
|
August 1, 1979
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer
R F Ozols, G Y Locker, J H Doroshow, et al.
Cancer
|
November 15, 1981
Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film
J H Doroshow, G Y Locker, D E Gaasterland, et al.
Cancer Treatment Reports
|
February 1, 1986
Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial
G Y Locker, V Lanzotti, J D Khandekar, et al.
Cancer Treatment Reports
|
September 1, 1987
Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial
G Y Locker, L Kilton, T Hoeltgen, et al.
The Lancet. Oncology
|
August 5, 2006
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
, A Buzdar, A Howell, et al.
Cancer Treatment Reports
|
February 1, 1979
Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin
R F Ozols, G Y Locker, J H Doroshow, et al.
Cancer Treatment Reports
|
June 1, 1987
Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial
G Y Locker, J Khandekar, S Krauss, et al.
Investigational New Drugs
|
January 1, 1994
High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial
G Y Locker, L Kilton, J D Khandekar, et al.
Lancet (London, England)
|
January 11, 2005
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell, J Cuzick, M Baum, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Cancer Treatment Reports
|
October 1, 1984
Phase II trial of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial
G Y Locker, V Lanzotti, D Sweet, et al.
Cancer Research
|
August 1, 1979
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer
R F Ozols, G Y Locker, J H Doroshow, et al.
Cancer
|
November 15, 1981
Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film
J H Doroshow, G Y Locker, D E Gaasterland, et al.
Cancer Treatment Reports
|
February 1, 1986
Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial
G Y Locker, V Lanzotti, J D Khandekar, et al.
Cancer Treatment Reports
|
September 1, 1987
Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial
G Y Locker, L Kilton, T Hoeltgen, et al.
The Lancet. Oncology
|
August 5, 2006
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
, A Buzdar, A Howell, et al.
Cancer Treatment Reports
|
February 1, 1979
Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin
R F Ozols, G Y Locker, J H Doroshow, et al.
Cancer Treatment Reports
|
June 1, 1987
Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial
G Y Locker, J Khandekar, S Krauss, et al.
Investigational New Drugs
|
January 1, 1994
High-dose aminothiadiazole in advanced colorectal cancer. An Illinois Cancer Center phase II trial
G Y Locker, L Kilton, J D Khandekar, et al.
Lancet (London, England)
|
January 11, 2005
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell, J Cuzick, M Baum, et al.
Page
of 3